Source-grounded facts extracted from Envoy Medical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 19, 2026, the Company received a second staff notification from Nasdaq informing the Company that, although the Company had not met the Bid Price Requirement by the Compliance Date, the Company is eligible for an add”
Envoy Medical, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $39.
“Net Revenue was $39 for the three months ended March 31, 2026.”
Envoy Medical, Inc. engaged EisnerAmper LLP as its auditor.
“Upon the approval of the Committee, the Company entered into an engagement agreement with EisnerAmper, dated March 26, 2026, to serve as the Company’s independent public accounting firm for the fiscal year ending December 31, 2026.”
Envoy Medical, Inc. dismissed Grant Thornton LLP as its auditor.
“On March 25, 2026, the Company notified Grant Thornton LLP (“ Grant Thornton ”) of its dismissal as the Company’s independent registered public accounting firm, effective as of the date of the notice.”
Envoy Medical, Inc. reported full year ended December 31, 2025 results: revenue $241.
“Net Revenue was $241 as of December 31, 2025 compared to $225 for year ended December 31, 2024.”
Envoy Medical, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(2), 5815(d)(4)(B)).
“February 23, 2026, Envoy Medical, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a discretionary panel monitor for a period of one year from February 12, 2026.”
Envoy Medical, Inc. entered into Pre-Funded Warrants with certain investors valued at 27,053,850 Pre-Funded Warrants to purchase 27,053,850 shares of Common Stock at an exercise price of (effective 2026-02-11).
“ii) 27,053,850 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 27,053,850 shares of Common Stock, (iii) 45,000,000 Series A-1 Warrants to purchase 45,000,000 shares of Common Stock and/or pre-funded warrants (the “ Series”
Envoy Medical, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at exclusive placement agent for the Offering (effective 2025-09-17).
“H.C. Wainwright & Co., LLC (“ Wainwright ”) acted as the exclusive placement agent for the Offering pursuant to an Engagement Letter, dated September 17, 2025, as amended on December 17, 2025, February 9, 2026 and February 11, 2026 (the “ Engagement Letter ”).”
Envoy Medical, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds of approximately $30.0 million from the Offering (effective 2026-02-11).
“On February 11, 2026, Envoy Medical, Inc., a Delaware corporation (the “ Company ”), commenced a best efforts public offering (the “ Offering ”) of an aggregate of (i) 47,946,150 shares (the “ Shares ”) of the Company’s Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), (ii) 27,053,850 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 27,053,850 shares of Common Stock, (iii) 45,000,000 Series A-1 Warrants to purchase 45,000,000 shares of Common Stock and/or pre-funded warrants (the “ Series A-1 Warrants ”), and (iv) 75,000,000 Series A-2 Warrants to purchase 75,000,000 shares of Common Stock and/or pre-funded warrants (the “ Series A-2 Warrants ” and, together with the Series A-1 Warrants, the “ Common Warrants ”).”
Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“November 19, 2025, Envoy Medical, Inc. (the “Company”) received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the "Common Stock"), has failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Common Stock on The Nasda”
Envoy Medical, Inc. received a nasdaq extension granted notice regarding market value (rules 5550(b)(2)).
“October 23, 2025, the Nasdaq Hearings Panel (the “Panel”) notified Envoy Medical, Inc. (the “Company) that it has granted the Company’s request for an exception to demonstrate compliance with the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) for continued listing through February 23, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the”
Envoy Medical, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“August 26, 2025, the Company received a determination letter from Nasdaq notifying the Company that it has not regained compliance with the MVLS Requirement within the 180 day cure period. The determination letter informed the Company that it can request a hearing regarding Nasdaq’s determination with a Hearings Panel (the “Panel”) by September 2, 2025 to discuss how the Company believes it will regain compliance and why the Company believes the Hearing Panel should grant an extension. If the Company did not make a request to the Hearings Panel, the trading of the Company’s securities would be”
Envoy Medical, Inc. incurred loan of $5,000,000 with GAT Funding, LLC.
“On June 26, 2025, Envoy Medical, Inc. (the “Company”) drew the remaining $5,000,000 of available principal under the promissory note, dated as of March 6, 2025 (the “Note”), between the Company and GAT Funding, LLC (“GAT”).”
Brent T. Lucas was appointed as principal financial officer at Envoy Medical, Inc..
“The Company’s Chief Executive Officer, Brent T. Lucas, will serve as principal financial officer on an interim basis until a successor Chief Financial Officer is appointed.”
David R. Wells departed as Chief Financial Officer at Envoy Medical, Inc..
“Effective May 16, 2025, David R. Wells ceased serving as Chief Financial Officer of Envoy Medical, Inc.”
Michael Crowe was appointed as Director at Envoy Medical, Inc..
“On June 7, 2024, the Board appointed Michael Crowe to fill the vacancy created by Dr. Haring-Smith’s resignation.”
Whitney Haring-Smith resigned as Director at Envoy Medical, Inc..
“On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the “Board”) effective immediately.”
Envoy Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $59 thousand.
“forward to the prospect of disrupting the hearing industry with new competition and significant innovation.” Financial Results for the Quarter Ended March 31, 2024 Revenue was $59 thousand compared to $78 thousand for the same period in 2023, the decrease is primarily due to a decrease in the number of battery replacement requests received during the three months”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.